News

Upadacitinib has shown promising results for a variety of diseases such as severe atopic dermatitis and psoriatic arthritis, but its future remains uncertain.

The treatment met all 5 primary efficacy endpoints as part of the ASCEND program.

This patient group was at an increased risk for future exposure to systemic corticosteroids and anti-TNF biologics.

Data show risk factors included education level and increased glucose level did not have signficant impact on BMI and body fat of children.

Enrollees with OUD receiving medication treatment increased from 47.8% in 2014 to 57.1% in 2018

The FDA Cardiovascular and Renal Drugs Advisory Committee cited concerns over an increase in thrombotic events.

A new statement from the AHA and American Stroke Association stressed the need to address gaps in care that may lead to high risk of stroke recurrence.

The new kinoid vaccine has shown positive results in mice with human proteins, and the France-based team remain optimistic of human trials in the future.

Patients with glucocorticoid-refractory or -dependent chronic GVHD are more likely to experience complete or partial response with the JAK inhibitor than with control therapies.

Biologic use was not associated with an increased risk of hepatitis B virus flares.

Metabolomic and preclinical studies have indicated that branched-chain amino acids may protect against neurodegenerative diseases.

Roughly 60% of participants in the SINUS-24 and SINUS-52 trials reported improvements in the severity of loss-of-taste.

Data show both microvascular and macrovascular outcomes were significantly improved following bariatric intervention in patients with obesity.

Patients with IBD have an increased risk of developing a C difficile infection in comparison to the general population.

More than 56% of these patients enrolled in TARGET-NASH were being treated with statins.

Researchers in the UK recommend early detection and treatment of food allergy and sensitization to avoid complications in adulthood.

While the nerve disease is not life threatening, patients may experience considerable poor quality of life and emotional distress.

Research on the effect of methotrexate and other immunosuppressants in regard to the COVID-19 vaccine are encouraging yet unfinished.

About 25% of IBD patients with CDI had a history of antibiotic use.

A new report sheds light on the gaps in knowledge and research surrounding the reproductive health of girls and women with sickle cell disease.

Dr. Jorge Maspero speaks of the complications of severe chronic rhinosinusitis with nasal polyps and how dupilumab could improve the daily struggles patients face.

There are several cholesterol lowering drugs available for this patient population.

Retinal laser photocoagulation may be performed by a specialist from a distance using telemedicine platforms.

One theory as to why IBD patients are more susceptible to CDI is the use of immunosuppressant treatments.

Despite a global decrease in asthma deaths, researchers say the disease is particularly threatening to patients with atopic dermatitis.

This edition of HCPLive® State of the Science involves 3 experts discussing different trends in IBD treatments and care.

Dr. Jorge Maspero speaks of the recent successes of the two newest trials, and what they could mean for the future of chronic rhinosinusitis management.

Adults who have received at least one prior line of therapy may receive daratumumab and hyaluronidase-fihj combined with pomalidomide and dexamethasone.